Co-design of an intervention aimed to Activate pharmacists to review medication-related problems: The ACTMed co-design and pilot study

Not Applicable

Active, not recruiting

• Conditions: medication related problems; Public Health - Health service research

• Registration Number: ACTRN12622000595718
• Lead Sponsor: Dr Jean Spinks

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-21
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

a) Consumer participants
•Aged 18 years or over
•Able to provide full informed consent
•Self-identified as / or a carer to an individual having a complicated or burdensome medicine regime OR having had a previous lived experience of a medicine problem

b) General Practices
•use of Best Practice or Medical Director software (not cloud based);
•an available computer to install GRHANITE® data extraction software.

c) Health practitioner participants
•Aged 18 years or over
•Able to provide full informed consent
•A registered health practitioner (GPs and pharmacists will be included at a minimum)
•Practice support staff such as practice managers will also be eligible to participate in practice workshops

Exclusion Criteria

a) Consumer participants
•Unable to provide fully informed consent

b) General Practices
•do not use Best Practice or Medical Director software (not cloud based);
•no computer available to install GRHANITE® data extraction software.

c) Health practitioner participants
•Unable to provide full informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Any change in the proportion of individuals from the exposed population with any serious medication-related problems at baseline compared to a 3 month follow-up (within the pilot phase). This will be determined within the Future Health Today software platform which will be able to determine: the exposed population and the proportion with a medication-related problem within a 24 hour time-period (software updates are run nightly). The definition of 'exposed' and 'medicine-related problem' will be determined by the clinical indicators selected during the co-design phase.[3 months post pilot start date]

Secondary Outcome Measures

Name	Time	Method
To determine whether the ACTMed intervention is ready for evaluation in the stepped-wedge randomised controlled trial phase. This will be assessed as a composite of usability of the intervention as measured using the System Usability Scale, acceptability of the intervention determined by qualitative interviews with consumers and health practitioners, and effectiveness of the intervention determined by the primary outcome measure.[3 months post pilot start date. ]